Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial

Launched by MEDTRONIC CARDIOVASCULAR · May 12, 2022

Keywords

ClinConnect Summary

The ADVANCE Trial is a study comparing two different types of stent graft systems used for treating abdominal aortic aneurysms (AAAs), which are bulges in the aorta that can be dangerous if they grow too large. This trial specifically looks at the Endurant II/IIs Stent Graft Systems and the Gore Excluder/Excluder Conformable AAA Endoprosthesis. If you are a man with an aneurysm measuring 5.5 centimeters or more, or a woman with one measuring 5.0 centimeters or more, you might be eligible to participate in this study. To join, you would need to agree to attend all follow-up visits and have a suitable type of aneurysm as determined by your doctor.

Participants in this trial can expect regular check-ups and imaging tests to monitor their condition after receiving one of the stent grafts. The main goal is to gather important information about how well each device works over time. It's important to note that certain health conditions, previous treatments, or specific anatomical features may disqualify someone from joining the study. If you're interested in learning more about this trial and whether you qualify, it’s best to talk to your doctor.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subject and the treating physician agree that the subject will return for all required followup visits
• • Subject or legal representative or consultee, as applicable, has consented for trial participation and signed the Informed Consent approved by the sponsor and by the Ethics Committee/Institutional Review Board
• • Subject has an aneurysm diameter of ≥ 5 cm (if woman) ≥ 5.5 cm (if man)
• • Subject's AAA anatomy is appropriate for both Medtronic Endurant II/IIs Stent Graft System and Gore Excluder/Excluder Conformable AAA Endoprosthesis as per assessment of both treating physician and Core Lab in accordance with the overlapping commercially available IFUs per applicable region.
• Exclusion Criteria:
• • Subject is participating in an investigational drug or device study which may bias or interfere with the endpoints and follow-up of this trial
• • Subject has an estimated life expectancy of ≤ 3 years as judged by the investigator
• * Subject has an aneurysm that is:
• • 1. Suprarenal/pararenal/juxtarenal
• • 2. Isolated ilio-femoral
• • 3. Mycotic
• • 4. Inflammatory
• • 5. Pseudoaneurysm
• • 6. Concomitant or prior dissection involving the abdominal aorta or iliac arteries
• • 7. Ruptured
• • 8. Symptomatic AAA
• • Subject has significant thrombus and / or calcium at the arterial implantation sites, specifically the proximal aortic neck and distal iliac artery interface. Significant thrombus may be quantified as thrombus ≥ 2 mm in thickness and / or ≥ 25% of the vessel circumference in the intended seal zone of the aortic neck.
• • Subject requires emergent aneurysm treatment, for example, trauma or rupture
• • Subject with connective tissue disease that may have caused the aneurysm e.g. Marfan syndrome, Ehlers-Danlos, Loeys-Dietz syndrome
• • Subject has previously undergone surgical or endovascular treatment in the abdominal aorta or the iliac arteries for aneurysm or occlusive disease
• • Planned use of aorto-uni-iliac (AUI) main body device
• • Any planned additional device (apart from the main body, limb stent graft and extensions per assigned treatment per randomization) during index or staged procedure, e.g., endostaple or anchor, Iliac branch endoprosthesis, embolization, etc.
• • Planned coverage of the internal iliac artery/arteries
• • Subject has an estimated glomerular filtration rate (eGFR) \< 45 ml/min/1.73m2 or subject is on dialysis
• • Subject has a systemic infection who may be at increased risk of endovascular graft infection, per investigator's discretion
• • Subject has a psychiatric or other condition that may interfere with the trial, per investigator's discretion
• • Subject is of childbearing potential in whom pregnancy cannot be excluded
• • Subject has a known hypersensitivity or contraindication to anticoagulants, anti-platelets, or contrast media, which is not amenable to pre-treatment
• • Subject belongs to a vulnerable population per investigator's judgment
• • Subject has an active COVID-19 infection or relevant history of COVID- 19